I-Flow To Present at the Sidoti & Company 4th Annual Boston Emerging Growth Institutional Investor Forum Tuesday, June 5, 2007 at 11:00 A.M. EDT
Posted on: Wednesday, 30 May 2007, 12:00 CDT
I-FLOW CORPORATION (NASDAQ:IFLO) announced today that it will address institutional shareholders and other investors at the Sidoti & Company 4th Annual Boston Emerging Growth Institutional Forum on Tuesday, June 5, 2007 at 11:00 a.m. EDT. The Conference is scheduled for June 5th at the Ritz-Carlton Boston Common, 10 Avery Street, Boston, MA.
Donald M. Earhart, I-Flow's Chairman, President, and Chief Executive Officer, will make a presentation describing the Company's growth strategies, financial outlook and market opportunities. The presentation will not be webcast.
I-Flow Corporation is an emerging leader in post-surgical pain relief and is redefining recovery following surgery. The Company's ON-Q® PainBuster® Post-Op Pain Relief System provides targeted pain relief after surgery only where the body needs it, automatically delivering a non-narcotic, pain-numbing medication directly to an incision site for up to five days. The anesthetic is administered through a specially-designed, proprietary catheter -- like the new ON-Q SilverSoakerTM which offers enhanced antimicrobial properties to reduce the risk of infection by providing an added layer of protection -- inserted by a surgeon during surgery. ON-Q PainBuster is cleared for use by the U.S. Food & Drug Administration (FDA), and is labeled to reduce pain significantly better than narcotics and to significantly reduce narcotics intake after surgery.
About I-Flow
I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost ambulatory infusion systems that are redefining the standard of care by providing life enhancing, cost-effective solutions for pain relief.
"Safe Harbor" Statement
Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes", "anticipates", or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release, which seek to advise interested parties of the risks, and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: successful consummation of the previously announced sale of InfuSystem, Inc; physician acceptance of infusion-based therapeutic regimens; implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.
Source: Business Wire
Related Articles
- Severe And Chronic Pain In Multiple Areas Associated With Increased Risk Of Falls In Older Adults
- Red Wings forward needs hernia surgery
- Metoprolol at Surgery May Increase Risk
- Anesiva to Present Additional Phase 2 Data at American Pain Society Meeting on 4975 for Treatment of Post-Surgical Pain Following Knee Replacement Surgery
- Real-Life Stories Support New Position Statement By Society of Vascular Surgery on Importance of Screening
- American Heart Association Scientific Statement: AHA Statement Recommends Doctors Change Approach to Prescribing Pain Relievers for Patients With or at Risk for Heart Disease
- Obesity Surgery Has Many Risks
- Obesity surgery lowers heart risk, US study shows
- Obesity Surgery Lowers Heart Risk
- Jackson & Harris Survey: Physicians Look to New President for Medical Liability Relief
User Comments (0)

RSS Feeds